Company
Cynata Therapeutics Ltd
ASX:CYP
Cynata Therapeutics Limited is a clinical-stage biotechnology company transforming regenerative medicine through our proprietary Cymerus™ platform technology.
39 stories
Proactive Biotech Webinar attracts strong response
Presenting companies were Cynata Therapeutics Ltd, Recce Pharmaceuticals Ltd and Pharmaxis Ltd (ASX:PXS).
Cynata Therapeutics aims for commercial production of cutting-edge STEM cell products
The Australian clinical-stage stem cell and regenerative medicine company is focused on the development of stem cell platform technology for commercial production with the help of pharmaceutical partner Fuji Film.
Cynata Therapeutics to talk stem cell therapies at Proactive’s CEO Sessions
Cynata’s managing director Dr Ross Macdonald will present at Proactive’s CEO Sessions in Sydney on February 3 and Melbourne on February 4.
Cynata Therapeutics welcomes UK Regulatory Authority approval of Phase 2 clinical trial in critical limb ischaemia
In a preclinical study in a mouse model of CLI, treatment with Cymerus MSCs led to significantly higher blood flow in the ischaemic limb and protection against muscle damage, fibrosis and limb loss.
Cynata Therapeutics awarded grant to progress stem cell therapies for coronary artery disease
The company is an Australian clinical-stage stem cell and regenerative medicine corporation focused on the development of therapies based on Cymerus – a therapeutic stem cell platform technology.
Cynata Therapeutics' stem cell treatment helps reduce adverse reactions to cancer immunotherapy
The regenerative medicine company plans to further develop the treatment through partnerships with companies commercialising cancer immunotherapies.
Investments and investor services
Small and mid-cap companies will be showcased during inaugural ASX conference
The inaugural ASX Small and Mid-Cap Conference will be held in Sydney on Thursday, September 6.
Cynata Therapeutics treats final patient in stem cell clinical trial
Cynata is an Australian clinical-stage stem cell and regenerative medicine company.
Cynata Therapeutics granted another patent for its unique stem cell technology
Cynata’s lead product was recently granted Orphan Drug Designation by the US FDA.
Cynata Therapeutics' shares surge in response to positive Cymerus trial data
The global annual market for GvHD treatment is expected to be US$500 million by 2021.
HC Wainwright repeats 'buy' on Cynata as ongoing trial is cleared by data safety monitoring board
Analyst Raghuram Selvaraju repeated a 'buy' stance and targets A$1.50 for the shares
Cynata Therapeutics wins U.S. patent for stem cell technology
The company's patent covers methods to efficiently manufacture stem cells at scale.
Cynata Therapeutics process meets Health Canada expectations
The company has developed a unique method to produce stem cells.
Cynata Therapeutics Ltd crosses major milestone in the U.S.
The company recently announced a strategic agreement with Fujifilm.
Cynata Therapeutics achieves progress in stem cell technology
The global regenerative medicine market was worth US$18.9 billion in 2016.
Cynata Therapeutics to reveal details on clinical trial
The halt will remain in place until Wednesday 17th May 2017.
Cynata Therapeutics: Access latest PPT from Proactive's CEO Sessions
Dr Ross Macdonald talked stemcell research with investors.
Cobalt Blue to outline resource growth strategy at Proactive's CEO Sessions
Find out more from Joe Kaderavek at Proactive's CEO Sessions.
White Cliff Minerals brings gold, lithium, nickel to Proactive's CEO Sessions
Find out more from Todd Hibberd at Proactive's CEO Sessions.
Bluechiip brings wireless tracking technology to Proactive's CEO Sessions
Find out more from Andrew McLellan at Proactive's CEO Sessions.
Proactive's CEO Spotlight Sessions: Cynata, Bluechiip, White Cliff, Legend Mining
Proactive's CEO Spotlight Sessions are back again giving investors the opportunity to hear the latest news flow from directors, and what to expect next.
Legend Mining brings Fraser Range nickel-copper hunt to Proactive's CEO Sessions
Find out more from Mark Wilson at Proactive's CEO Sessions.
Cynata Therapeutics talks stem cell research at Proactive's CEO Sessions
Find out more from Dr Ross Macdonald at Proactive's CEO Sessions.
Cynata Therapeutics secures funds to progress stem cell technology
Cynata Therapeutics (ASX:CYP) has successfully completed a placement to sophisticated and institutional investors to raise $6 million, at $0.65 per share.
Cynata Therapeutics to raise capital
Cynata Therapeutics (ASX:CYP) has been granted a trading halt by the ASX, pending details on a capital raising.
Cynata Therapeutics to begin stem cell product trial in England
Cynata Therapeutics (ASX:CYP) has received approval from the National Health Service (NHS), England for the Phase 1 trial in patients with steroid-resistant acute GvHD (graft versus host disease).